EIDX Eidos Therapeutics Inc.
Upcoming Catalysts
| Drug | Stage | Catalyst Date |
|---|---|---|
|
Acoramidis (AG10) - ATTRibute-CM
ATTR-CM
|
Phase 3
Phase 3
|
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
|
Drug Pipeline
| Drug | Stage | Notes |
|---|---|---|
|
AG10 / BBP-265
ATTR-PN
|
Phase 2
Phase 2
|
Phase 3 trial planned for 2H 2020.
|
Latest News
-
View Full Article Hide Full Article
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
MyoKardia, Inc. (NASDAQ:MYOK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bristol-Myers Squibb Company for $225.50 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/myokardia-inc-myok-stock-merger-bristol-myers/.
Eidos Therapeutics, Inc. (NASDAQ:EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc. Under the merger agreement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos common stock owned. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/eidos-therapeutics-inc-eidx-stock-merger-bridgebio/.
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/cellular-biomedicine-group-inc-cbmg-stock-merger/.
Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-halper-sadeh-llp-is-investigating-the-following-companies-investors-are-encouraged-to-contact-the-firm--myok-eidx-cbmg-301156147.htmlSOURCE Halper Sadeh LLP
-
View Full Article Hide Full Article
Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-stage biotech company Eidos Therapeutics. (NASDAQ:EIDX).
If you currently own shares of Eidos and want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll free number (800) 321-0476 or via email at [email protected].
About the Firm
Labaton Sucharow LLP is one of the world's leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at http://www.labaton.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005579/en/
-
View Full Article Hide Full Article
PHILADELPHIA, Oct. 7, 2020 /PRNewswire/ -- Kaskela Law LLC is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ:EIDX) on behalf of the company's shareholders.
On October 5, 2020, Eidos announced that it had entered into a definitive agreement under which BridgeBio Pharma, Inc. ("BridgeBio") will acquire all of the outstanding shares of common stock of Eidos it does not already own, representing approximately 36.3% of Eidos' outstanding shares. According to the announcement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash per Eidos share in the proposed transaction. Following the closing of the proposed transaction, shares of Eidos' common stock will no longer be publicly traded.
The investigation seeks to determine whether Eidos stockholders (i) will be receiving adequate consideration for their shares and (ii) are receiving all material information in connection with the proposed transaction.
Eidos shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by email at [email protected], to discuss this investigation and their legal rights and options with respect to this transaction. Additional information may also be found at http://kaskelalaw.com/case/eidos-therapeutics/.
Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
CONTACT:
D. Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 258 – 1585
(888) 715 – 1740
www.kaskelalaw.com
[email protected]This notice may constitute attorney advertising in certain jurisdictions.
View original content:http://www.prnewswire.com/news-releases/shareholder-alert-kaskela-law-llc-announces-investigation-of-eidos-therapeutics-inc-eidx-and-encourages-eidx-shareholders-to-contact-the-firm-301147539.htmlSOURCE Kaskela Law LLC
-
View Full Article Hide Full Article
NEW YORK, Oct. 6, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies:
- American Renal Associates Holdings, Inc. (NYSE:ARA)
American Renal Associates Holdings has agreed to be acquired by affiliates of Nautic Partners. Under the proposed transaction, shareholders of American Renal will receive $11.50 in cash for every share owned.
- Eidos Therapeutics, Inc. (NASDAQ: EIDX)
Eidos Therapeutics has agreed to be acquired by BridgeBio Pharma. Under the proposed transaction, shareholders of Eidos will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash per share owned.
- Montage Resources Corporation (NYSE:MR)
A registration statement was recently filed with the SEC regarding Southwestern Energy Company's merger with Montage Resources. Upon completion of the merger, shareholders of Montage Resources will receive 1.8656 shares of Southwestern Energy per share owned. The investigation concerns whether Montage's board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price.
- MyoKardia, Inc. (NASDAQ:MYOK)
MyoKardia has agreed to be acquired by Bristol-Myers Squibb. Under the proposed transaction, shareholders of MyoKardia will receive $225.00 in cash per share owned.
Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process.
Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at [email protected] or telephone at (212) 709-8245. The consultation and case are free with no obligation to you. Moore Kuehn pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Moore Kuehn is a 5-star Google rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please visit http://www.moorekuehn.com/practice/new-york-securities-litigation/.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Moore Kuehn, PLLC
Justin Kuehn, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
[email protected]
(212) 709-8245
View original content to download multimedia:http://www.prnewswire.com/news-releases/moore-kuehn-encourages-ara-eidx-mr-and-myok-investors-to-contact-law-firm-301146935.htmlSOURCE Moore Kuehn, PLLC
-
View Full Article Hide Full Article
NEW YORK, Oct. 6, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating:
MyoKardia, Inc. (NASDAQ:MYOK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bristol-Myers Squibb Company for $225.50 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/myokardia-inc-myok-stock-merger-bristol-myers/.
Eidos Therapeutics, Inc. (NASDAQ:EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc. Under the merger agreement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos common stock owned. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/eidos-therapeutics-inc-eidx-stock-merger-bridgebio/.
Proteostasis Therapeutics, Inc. (NASDAQ:PTI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Yumanity Therapeutics. Under the terms of the merger agreement, Proteostasis will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of Proteostasis common stock, with existing Proteostasis shareholders expected to own approximately 32.5% of the combined company. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/proteostasis-therapeutics-inc-pti-yumanity-stock-merger/.
GCI Liberty, Inc. (NASDAQ:GLIBA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Liberty Broadband Corporation. Visit our website to learn more and participate in an action: https://halpersadeh.com/actions/gci-liberty-inc-gliba-stock-merger-liberty-broadband-technologies/.
Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llp-continues-to-investigate-the-following-mergers-shareholders-are-encouraged-to-contact-the-firm---myok-eidx-pti-gliba-301146877.htmlSOURCE Halper Sadeh LLP